The Dutch startup ecosystem continues to captivate international attention. The State of Dutch Tech 2024 report reveals that in 2023, acquisitions in the Dutch startup ecosystem saw a notable increase ...

Today’s news follows the previous arrivals of 18 other senior leaders announced in June and Klick Media President Ray Rosti in July, highlighting the company’s continued commitment to delivering ...

Last Friday, the Medicines and Healthcare Products Regulatory Agency approved Merck & Co Inc’s (NYSE:MRK) Winrevair (sotatercept) for adult patients with pulmonary arterial hypertension (PAH).

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and ...

The stock's fall snapped a two-day winning streak.

Merck's strong financial performance in oncology and vaccines drove a 9% sales increase earlier in Q1 of 2024, despite challenges with other products. Promising future developments include ...

Merck & Co. snagged a potential drug in the burgeoning market for obesity medications in a deal worth as much as $2 billion. Under the terms of the deal, the company will gain the exclusive global ...

In a day that already included discontinuations from Roche and Foghorn Therapeutics, Merck & Co. rounded out Monday by announcing the termination of two late-stage cancer assets. The New Jersey ...

Dec 18 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing deal worth up to $2 billion for Chinese biotech Hansoh Pharma's (3692.HK), opens new tab experimental oral drug to treat ...

Merck (NYSE:MRK) and Chinese biopharmaceutical company Hansoh Pharma (OTCPK:HNSPF) announced a global licensing deal on Wednesday to develop HS-10535, an oral GLP-1 receptor agonist targeted at ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...